CVC Strategic Opportunities Sells Entire Stake in Genetic S.p.A., Strengthening the Company’s Global Position

CVC Strategic Opportunities Sells Entire Stake in Genetic S.p.A., Strengthening the Company’s Global Position

(IN BRIEF) CVC Strategic Opportunities II has successfully exited its investment in Genetic S.p.A., a pharmaceutical CDMO specializing in Respiratory, Ophthalmic, and Oncology therapeutic products. The exit sees NB Renaissance and NB Aurora joining the Pavese family as shareholders. Under CVC’s ownership, Genetic expanded internationally, grew its R&D pipeline, and more than doubled its revenues. The transaction is pending regulatory approval.

(PRESS RELEASE) LUXEMBOURG, 20-May-2025 — /EuropaWire/ — CVC Strategic Opportunities II (“StratOps II”) today announced the successful sale of its entire stake in Genetic S.p.A. (“Genetic”), a leading pharmaceutical contract development and manufacturing organisation (CDMO) that specialises in the development and supply of products in the Respiratory, Ophthalmic, and Oncology therapeutic areas.

This transaction marks a successful exit for CVC after a fruitful partnership with Genetic and the founding Pavese family. Following the exit, NB Renaissance and NB Aurora will become new shareholders alongside the Pavese family, which will increase its ownership stake in the company.

Based in Fisciano, Italy, Genetic is an integrated pharmaceutical CDMO focused on the research, development, manufacturing, and licensing of pharmaceutical products and medical devices. The company’s primary expertise lies in the development of Respiratory and Ophthalmology products, which are delivered using Blow-Fill-Seal technology, Metered Dose Inhalers, nasal sprays, and eye drop/collyrium technologies. Genetic’s products are marketed by a network of leading pharmaceutical partners worldwide, as well as through its own distribution arm, Genetic Farma, in Italy, where they are often marketed under well-recognised local brand names.

During CVC’s partnership with Genetic and the Pavese family, the company expanded significantly. Its international presence grew from 20 countries in 2020 to over 40 today, and its R&D pipeline was broadened. Additionally, Genetic committed to building a new production facility to meet growing global demand for its products. As a result of these strategic initiatives, Genetic’s revenues have more than doubled under CVC’s ownership.

Michael Lavrysen, Partner at CVC Strategic Opportunities, said: “We are incredibly proud to have supported Genetic’s growth over the past years. Through targeted investments in R&D, the company has developed into a prominent international CDMO. This successful exit reflects the strong collaboration between our teams, Rocco Pavese, and his management team. We wish Genetic continued success as it enters the next phase of its journey.”

Giorgio De Palma, Partner at CVC Italy, added: “Genetic exemplifies the type of high-quality, founder-led businesses we seek to support in the Italian market. It has been a privilege to work with such a capable team, helping the company expand its international reach while staying true to its Italian roots. We are thrilled to have contributed to the company’s success and look forward to seeing its continued growth.”

Rocco Pavese, CEO and founder of Genetic, commented: “Partnering with CVC in 2020 marked a key moment in our growth trajectory, and I’m proud of the progress we’ve made over the last five years.” Francesca Pavese, Head of Business Development and Internationalisation at Genetic, added: “We are grateful to CVC for their support in helping us professionalise and expand internationally. As we move forward under continued family ownership, we are excited about our future growth, new investments, and the development of therapeutic solutions that can improve patients’ lives.”

The transaction is subject to customary regulatory approvals.

CVC was advised by Rothschild & Co., PedersoliGattai, FRM Tax, BCG, and PwC.

Media Contact:

Patrick Humphris
Managing Director, Head of Corporate Affairs
CVC
Tel: +44 204 576 9526
phumphris@cvc.com

SOURCE: CVC